NL8900779A - Eiwit dat de werking van tumor necrose factor tegengaat, dna dat voor zulk eiwit codeert, een vector die zulk dna bevat, een met die vector getransformeerde gastheercel en een farmaceutisch preparaat dat dat eiwit bevat. - Google Patents

Eiwit dat de werking van tumor necrose factor tegengaat, dna dat voor zulk eiwit codeert, een vector die zulk dna bevat, een met die vector getransformeerde gastheercel en een farmaceutisch preparaat dat dat eiwit bevat. Download PDF

Info

Publication number
NL8900779A
NL8900779A NL8900779A NL8900779A NL8900779A NL 8900779 A NL8900779 A NL 8900779A NL 8900779 A NL8900779 A NL 8900779A NL 8900779 A NL8900779 A NL 8900779A NL 8900779 A NL8900779 A NL 8900779A
Authority
NL
Netherlands
Prior art keywords
protein
tnfa
tnfar
cells
dna
Prior art date
Application number
NL8900779A
Other languages
English (en)
Dutch (nl)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NL8900779A publication Critical patent/NL8900779A/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL8900779A 1988-03-31 1989-03-30 Eiwit dat de werking van tumor necrose factor tegengaat, dna dat voor zulk eiwit codeert, een vector die zulk dna bevat, een met die vector getransformeerde gastheercel en een farmaceutisch preparaat dat dat eiwit bevat. NL8900779A (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888807803A GB8807803D0 (en) 1988-03-31 1988-03-31 Biochemical product
GB8807803 1988-03-31

Publications (1)

Publication Number Publication Date
NL8900779A true NL8900779A (nl) 1989-10-16

Family

ID=10634493

Family Applications (1)

Application Number Title Priority Date Filing Date
NL8900779A NL8900779A (nl) 1988-03-31 1989-03-30 Eiwit dat de werking van tumor necrose factor tegengaat, dna dat voor zulk eiwit codeert, een vector die zulk dna bevat, een met die vector getransformeerde gastheercel en een farmaceutisch preparaat dat dat eiwit bevat.

Country Status (12)

Country Link
JP (1) JPH02117700A (de)
KR (1) KR890014125A (de)
AU (1) AU3228789A (de)
BE (1) BE1001845A4 (de)
DE (1) DE3910323A1 (de)
DK (1) DK156589A (de)
FR (1) FR2629345A1 (de)
GB (2) GB8807803D0 (de)
IL (1) IL89804A0 (de)
IT (1) IT1232827B (de)
NL (1) NL8900779A (de)
SE (1) SE8901115L (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5811261A (en) * 1988-09-12 1998-09-22 Yeda Research And Development Co. Ltd. Expression of the recombinant tumor necrosis factor binding protein I (TBP-I)
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
ATE289350T1 (de) 1989-04-21 2005-03-15 Amgen Inc Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) * 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US5945397A (en) * 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
AU630497B2 (en) * 1989-09-05 1992-10-29 Immunex Corporation Tumor necrosis factor-alpha and -beta receptors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
WO1992001002A1 (fr) * 1990-07-11 1992-01-23 Teijin Limited Inhibiteur de l'activite du facteur de la necrose tumorale et son procede de preparation
EP0480389A1 (de) * 1990-10-12 1992-04-15 Hoechst Aktiengesellschaft Inhibitoren für die Bildung von Tumor Nekrose Faktor, Verfahren zu deren Herstellung und deren Verwendung
JP2864434B2 (ja) * 1991-01-18 1999-03-03 サイナーゲン，インコーポレーテッド 腫瘍壊死因子媒介疾患の治療方法
WO1993004375A1 (en) * 1991-08-23 1993-03-04 Nchip, Inc. Burn-in technologies for unpackaged integrated circuits
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
ATE406176T1 (de) 1996-12-06 2008-09-15 Amgen Inc Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
ATE247974T1 (de) 1996-12-06 2003-09-15 Amgen Inc Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
PT2087908T (pt) 2001-06-26 2018-07-16 Amgen Inc Anticorpos contra opgl
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
JP2006517191A (ja) 2002-12-30 2006-07-20 アムジエン・インコーポレーテツド 共刺激因子を用いた併用療法
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
PL2523688T3 (pl) 2010-01-15 2018-04-30 Kirin-Amgen, Inc. Formulacja przeciwciała i reżimy terapeutyczne
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
EP3126392B1 (de) 2014-03-31 2019-09-11 Kirin-Amgen, Inc. Verfahren zur behandlung von nagel- und kopfhautpsoriasis

Also Published As

Publication number Publication date
BE1001845A4 (fr) 1990-03-20
IT1232827B (it) 1992-03-05
IT8947794A0 (it) 1989-03-30
SE8901115L (sv) 1989-10-01
JPH02117700A (ja) 1990-05-02
DK156589A (da) 1989-10-01
GB2218101A (en) 1989-11-08
KR890014125A (ko) 1989-10-21
DE3910323A1 (de) 1989-10-19
AU3228789A (en) 1989-10-05
DK156589D0 (da) 1989-03-30
IL89804A0 (en) 1989-09-28
SE8901115D0 (sv) 1989-03-30
GB8907148D0 (en) 1989-05-10
FR2629345A1 (fr) 1989-10-06
GB8807803D0 (en) 1988-05-05

Similar Documents

Publication Publication Date Title
NL8900779A (nl) Eiwit dat de werking van tumor necrose factor tegengaat, dna dat voor zulk eiwit codeert, een vector die zulk dna bevat, een met die vector getransformeerde gastheercel en een farmaceutisch preparaat dat dat eiwit bevat.
Beutler et al. Cachectin (tumor necrosis factor): a macrophage hormone governing cellular metabolism and inflammatory response
KR100392984B1 (ko) 유전자치료를위한단구-마크로파아지세포계로부터의재조합세포
ES2067486T5 (es) Proteina inhibidora de factor de necrosis tumoral (tnf) y su purificacion.
JPH0729937B2 (ja) プロテインｃシステムの遮断による、腫瘍増殖の阻害
Cannon et al. Rabbit IL-1. Cloning, expression, biologic properties, and transcription during endotoxemia.
JP4326534B2 (ja) 可溶性ｌｄｌリセプター
CN110396133B (zh) 一种以白介素12为活性成分的融合蛋白型药物前体
PT87237B (pt) Processo para a preparacao de proteinas bi-funcionais e de composicoes farmaceuticas que as contem
CA2186423C (en) Protein which induces interferon-gamma production by immunocompetent cell
EP0289572B1 (de) Verwendung von interleukin-1-proteinen gegen arthritis
JPH10262686A (ja) ポリペプチド
US20050063948A1 (en) Methods for targeting interleukin-12 to malignant endothelium
JP2001513636A (ja) ブロメラインの成分
JP3439490B2 (ja) 蛋白質とその蛋白質をコードするｄｎａ並びにその蛋白質の製造方法
US5157106A (en) N-terminal deletions of lymphotoxin, their preparation and use
JP2863265B2 (ja) インターロイキン１インヒビター
JP3030386B2 (ja) 抗ガン剤
CA2141598A1 (en) Method of inhibiting cell proliferation using apolipoprotein e
JP2002516087A (ja) 幾つかの重篤な疾患の治療のための医薬組成物を調製するための修飾されたリゾチームｃの使用
AU2001265082A1 (en) Thrombospondin-1 type 1 repeat polypeptides
JP2000504592A (ja) ヒトインターロイキン６（ｈＩＬ―６）に対するアンタゴニスト活性を有する、ｈＩＬ―６の突然変異体のアデノウイルスベクター、これを有する薬剤組成物およびその使用
JPH02138224A (ja) 血小板減少症治療剤
JP2697725B2 (ja) 悪性腫瘍治療用キット
JP2000505643A (ja) レクチン様性質を有する化合物およびその生物学的応用

Legal Events

Date Code Title Description
BV The patent application has lapsed